Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 11—November 2021
Research

Rapid Increase in SARS-CoV-2 P.1 Lineage Leading to Codominance with B.1.1.7 Lineage, British Columbia, Canada, January–April 2021

Catherine A. Hogan1Comments to Author , Agatha N. Jassem1, Hind Sbihi, Yayuk Joffres, John R. Tyson, Kyle Noftall, Marsha Taylor, Tracy Lee, Chris Fjell, Amanda Wilmer, John Galbraith, Marc G. Romney, Bonnie Henry, Mel Krajden, Eleni Galanis, Natalie Prystajecky, and Linda M.N. Hoang
Author affiliations: British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada (C.A. Hogan, A.N. Jassem, H. Sbihi, Y. Joffres, J.R. Tyson, K. Noftall, M. Taylor, T. Lee, C. Fjell, M. Krajden, E. Galanis, N. Prystajecky, L.M.N. Hoang); University of British Columbia, Vancouver (C.A. Hogan, A.N. Jassem, H. Sbihi, B. Henry, M. Krajden, E. Galanis, N. Prystajecky, L.M.N. Hoang); Kelowna General Hospital, Kelowna, British Columbia, Canada (A. Wilmer); Victoria General Hospital, Victoria, British Columbia, Canada (J. Galbraith); St. Paul’s Hospital, Vancouver (M.G. Romney); Ministry of Health, Victoria (B. Henry)

Main Article

Figure 2

Distribution of all severe acute respiratory syndrome coronavirus 2 cases and VOC cases by vaccination status, British Columbia, Canada, January–April 2021. Vaccinated persons included those who had received 1 dose of a 2-dose vaccine with diagnosis confirmed by PCR >21 days after the first dose (on the basis of specimen collection date). Stacked bars (left-hand y-axis) represent the absolute number of VOC cases and non-VOC cases. Solid lines (right-hand y-axis) show the percentage of VOC among all cases identified in a given week. Dotted lines show the date when VOC quantitative PCR (qPCR) including E484K mutation detection was adopted at the British Columbia Centre for Disease Control Public Health Laboratory. A) B.1.1.7 and non-VOC cases in nonvaccinated persons. B) B.1.1.7 and non-VOC cases in vaccinated persons. VOC cases in panels A and B included B.1.1.7 confirmed for lineage by whole-genome sequencing and presumptive B.1.1.7 positives based on a VOC qPCR result of N501Y-positive and E484K-negative. C) P.1 and non-VOC cases in nonvaccinated persons. D) P.1 and non-VOC cases in vaccinated persons. VOC cases in panels C and D included P.1 and B.1.351 confirmed for lineage by whole-genome sequencing and presumptive P.1 positives based on a VOC qPCR result of N501Y-positive and E484K-positive or K417T-positive. VOC, variant of concern.

Figure 2. Distribution of all severe acute respiratory syndrome coronavirus 2 cases and VOC cases by vaccination status, British Columbia, Canada, January–April 2021. Vaccinated persons included those who had received 1 dose of a 2-dose vaccine with diagnosis confirmed by PCR >21 days after the first dose (on the basis of specimen collection date). Stacked bars (left-hand y-axis) represent the absolute number of VOC cases and non-VOC cases. Solid lines (right-hand y-axis) show the percentage of VOC among all cases identified in a given week. Dotted lines show the date when VOC quantitative PCR (qPCR) including E484K mutation detection was adopted at the British Columbia Centre for Disease Control Public Health Laboratory. A) B.1.1.7 and non-VOC cases in nonvaccinated persons. B) B.1.1.7 and non-VOC cases in vaccinated persons. VOC cases in panels A and B included B.1.1.7 confirmed for lineage by whole-genome sequencing and presumptive B.1.1.7 positives based on a VOC qPCR result of N501Y-positive and E484K-negative. C) P.1 and non-VOC cases in nonvaccinated persons. D) P.1 and non-VOC cases in vaccinated persons. VOC cases in panels C and D included P.1 and B.1.351 confirmed for lineage by whole-genome sequencing and presumptive P.1 positives based on a VOC qPCR result of N501Y-positive and E484K-positive or K417T-positive. VOC, variant of concern.

Main Article

1These authors contributed equally to this article.

Page created: August 06, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external